The leader of the European Union's drugs office Guido Rasi said on Monday an underlying authorisation for U.S. pharmaceutical organization Gilead's remdesivir as a COVID-19 treatment could be conceded in coming days.

The European Medicines Agency (EMA) has just suggested the caring utilization of remdesivir, which permits a medication to be directed to patients even before it has been completely approved.

"It may be that a contingent market authorisation can be given in the coming days," Rasi told a meeting in the EU Parliament in Brussels.

Aside from remdesivir, Rasi said other potential medications against COVID-19 that might be accessible quick are those dependent on monoclonal antibodies, which can "kill" the new coronavirus (SARS-CoV-2) that causes the ailment COVID-19.